Abstract 3979: Metabolic Pathways Associated with Urinary Metabolite Biomarkers Differentiate Bladder Cancer Patients from Healthy Controls
Won Tae Kim,Seok Joong Yun,Chunri Yan,Pildu Jeong,Ye Hwan Kim,Il-Seok Lee,Sunghyouk Park,Sung-Kwon Moon,Yung-Hyun Choi,Young Deuk Choi,Jayoung Kim,Wun-Jae Kim
DOI: https://doi.org/10.1158/1538-7445.am2016-3979
IF: 11.2
2016-01-01
Cancer Research
Abstract:Abstract Our high-performance liquid chromatography-quadrupole time-of-flight mass spectrometry study identified bladder cancer (BCA)-specific urine metabolites, including carnitine, acylcarnitines, and melatonin. The objective of the current study was to determine which metabolic pathways are perturbed in BCA based on our previously identified urinary metabolome. Significant alterations in the carnitine-acylcarnitine and tryptophan metabolic pathways were detected in urine specimens from BCA patients compared to those of healthy controls. The expression of eight genes involved in the carnitine-acylcarnitine metabolic pathway (CPT1A, CPT1B, CPT1C, CPT2, SLC25A20, and CRAT) or tryptophan metabolism (TPH1 and IDO1) was assessed by RT-PCR in our BCA cohort (n = 135). CPT1B, CPT1C, SLC25A20, CRAT, TPH1, and IOD1 were significantly downregulated in tumor tissues compared to adjacent normal bladder tissues (p < 0.05 all) of patients with non-muscle invasive bladder cancer, whereas CPT1B, CPT1C, CRAT, and TPH1 were downregulated in those with muscle invasive bladder cancer (p < 0.05), with no changes in IDO1 expression. In this study, alterations in the expression of genes associated with the carnitine-acylcarnitine and tryptophan metabolic pathways, the most perturbed pathways in BCA, were determined. Our findings provide insight into the mechanisms underlying BCA-associated metabolic flux perturbation. Citation Format: Won Tae Kim, Seok Joong Yun, Chunri Yan, Pildu Jeong, Ye Hwan Kim, Il-Seok Lee, Sunghyouk Park, Sung-Kwon Moon, Yung-Hyun Choi, Young Deuk Choi, Jayoung Kim, Wun-Jae Kim. Metabolic pathways associated with urinary metabolite biomarkers differentiate bladder cancer patients from healthy controls. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3979.